Turn Therapeutics develops topical drug candidates for skin conditions and licenses wound care medical devices to partners. TTRX reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 23 | WBB Securities | Upgrade | Hold | |
| Sep 24 | LUCID CAPITAL MARKETS | Initiated | Buy | |
| Sep 14 | WBB Securities | Downgrade | Sell |
Whale Options Flow
90DNo whale options trades in TTRX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TTRX is in one of them and how their past TTRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TTRX in an article yet. Here's the latest on the wider market.
About Turn Therapeutics
Turn Therapeutics is a drug development company based in Westlake Village, California. It is developing GX-03, a topical treatment for inflammatory skin conditions, with programs aimed at moderate to severe eczema and nail fungus, known as onychomycosis. The company also licenses wound care and dermatitis medical devices to commercial partners, including Medline. Its drug candidate uses polyhexanide, a polymer with a long history of use in wound care.
- Headquarters
- Westlake Village, CA